Kosteneffektivität von Pravastatin in der koronaren Sekundärprävention bei Patienten mit Myokardinfarkt oder instabiler Angina pectoris in Deutschland Eine Analyse auf der Grundlage der LIPID-Studie

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Herz

• Publication date

  2000-08-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/PL00001961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

  2000cited by this paper
• Pharmakoökonomische Bewertung von Pravastatin in der koronaren Sekundärprävention bei Patienten mit Myokardinfarkt oder instabiler Angina Pectoris : eine Analyse auf der Grundlage der LIPID-Studie

  2000influential reference
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).

  1998cited by this paper
• Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

  1997cited by this paper
• The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin

  1997cited by this paper
• Recommendations for Reporting Cost-effectiveness Analyses

  1996cited by this paper
• KORONARE HERZKRANKHEIT: EIN SOZIOOKONOMISCHES PROBLEM?

  1996cited by this paper
• Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

  1996cited by this paper
• Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

  1996cited by this paper
• Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.

  1996cited by this paper
• Five-hundred life-saving interventions and their cost-effectiveness.

  1995cited by this paper
• Screening surgeons for HIV infection.

  1995cited by this paper
• Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).

  1993cited by this paper
• How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

  1992cited by this paper
• A Convenient Approximation of Life Expectancy

  1992cited by this paper
• Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.

  1991cited by this paper
• Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction.

  1988cited by this paper
• A Cost‐Effectiveness Analysis of Strategies to Reduce Infant Mortality

  1988cited by this paper
• A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

  1982cited by this paper
• Allocation of Resources to Manage Hypertension

  1977cited by this paper

• Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.

  2019cites this paper
• Gesundheitsökonomische Aspekte der Verschreibung von PCSK9-Hemmern

  2018cites this paper
• Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events

  2012cites this paper
• Cost of acute coronary syndrome in Switzerland in 2008.

  2012cites this paper
• Kosten-Effektivität von Atorvastatin bei Patienten mit akutem Koronarsyndrom - eine Analyse der PROVE IT-Studie

  2004cites this paper
• Kosteneffektivität von Atorvastatin zur Prävention der koronaren Herzkrankheit

  2004cites this paper